Ianalumab (VAY736)

ianalumab · Novartis Pharmaceuticals

Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for Ianalumab (VAY736), covering 2026-03-11 to 2026-06-03. Get the full timeline:

Most recent: Clinical Trial Update: Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome [Phase 3]

See pricing